TAK-901 T2709
Specifications
| 1mg/5mg/10mg/25mg/50mg/100mg |
Bioactivity:
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
CAS nr:
934541-31-8
Purity:
98%
Molecular Weight:
504,64
SMILES:
CCS(=O)(=O)c1cccc(c1)c1cc(C(=O)NC2CCN(C)CC2)c(C)c2c1c1cc(C)cnc1[nH]2
Formula:
C28H32N4O3S
Pathway:
Stem Cells,Angiogenesis,JAK/STAT signaling,Chromatin/Epigenetic,Angiogenesis,Chromatin/Epigenetic,Cell Cycle/Checkpoint,Tyrosine Kinase/Adaptors,Cell Cycle/Checkpoint
Target:
JAK,JAK,JAK,JAK,Src,Aurora Kinase,Aurora Kinase,Src,CDK
